Kathryn Golden, SVP Technical Operations & Cell Manufacturing, discusses how our opti-ox technology lends itself to scale through automation.
20.06.2023
Kathryn Golden, SVP Technical Operations & Cell Manufacturing, discusses how our opti-ox technology lends itself to scale through automation.
20.06.2023 Published by Scientist Live
iNews feature on consistency data presented at ISSCR by bit.bio
The piece covers bit.bio's breakthrough in industrialising the consistent manufacture of human cells and how this will transform h...
bit.bio featured in Forbes
The piece covers the launch of bit.bio's Custom ioDisease Model Cells at the SynBioBeta conference.
Industry responds to UK science strategy launch
Mark Kotter shares his thoughts in Labiotech on the importance of government support in enabling the UK to become a leading scienc...
Synbio and the opportunity within the UK’s innovation landscape
Mark Kotter, CEO shares his thoughts on Synbio and how the UK can support and expand this sector and become a powerhouse of scienc...
Key opinions - biotech in 2023: reasons for optimism
Our CEO gives his take on what's in store for the biotech industry in 2023 as part of this forward looking feature.
"Science Meets Design" episode on synthetic biology
This series explores the fascinating interface between science and design. Episode 2 looks at synthetic biology and features our ...
Lab space shortage threatens life science boom in Oxford & Cambridge
In this Financial Times piece our CEO is reflecting on raising concerns about the lab spaces for rent within science clusters.
Are you ready for Meatable’s cultivated pork sausages?
This piece covers how bit.bio's technology is also used by Meatable for their cultured meat products.
Loading form…